What Is the CMS Electronic Prior Authorization Rule for Drugs?
As of September 2026, CMS has proposed requiring Medicare Advantage, Medicaid, and marketplace payers to support electronic prior authorization for drugs covered under the medical benefit by October 1, 2027 (CMS-0062-P). For gastroenterology practices that administer biologic infusions for inflammatory bowel disease and other chronic conditions, this rule replaces the manual, fax-based prior authorization workflows that currently delay treatment starts and create administrative burden on both clinical and billing staff.
What it covers: The proposed rule extends electronic prior authorization to drugs billed under the medical benefit, including physician-administered biologics like infliximab (J1745), vedolizumab (J3380), and ustekinumab (J3357), which were excluded from the 2024 final rule that applied only to non-drug items and services.
What payers must do: Impacted payers would be required to build Prior Authorization APIs that let providers determine requirements, submit requests, and receive decisions electronically within their EHR systems.
Timeline: Standard prior authorization decisions for drugs would be required within 7 calendar days, and expedited decisions within 72 hours, with electronic interfaces going live by October 1, 2027.
What CMS Proposed for Drug Prior Authorization
On April 10, 2026, CMS released the 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule (CMS-0062-P). The rule proposes extending the electronic prior authorization requirements from the January 2024 final rule, which covered non-drug medical items and services, to include drugs covered under the medical benefit. For gastroenterology, this is the category that includes every biologic infusion, every physician-administered injection, and every specialty drug billed through the practice rather than a pharmacy.
The rule would require Medicare Advantage organizations, Medicaid managed care plans, CHIP managed care entities, and Qualified Health Plan issuers on the federal exchange to support electronic prior authorization for medical-benefit drugs using FHIR-based Prior Authorization APIs. For drugs processed under the pharmacy benefit, the rule relies on existing NCPDP SCRIPT standards. The proposed compliance date for both is October 1, 2027.
In our experience matching providers with gastroenterology billing partners, prior authorization for biologic infusions is consistently cited as the single most time-consuming administrative task in a GI practice. A single infliximab infusion can require 45 to 90 minutes of staff time for the prior authorization alone, including benefits verification, clinical documentation assembly, fax submission, follow-up calls, and appeal preparation when the initial request is denied. The electronic API requirement is designed to compress that cycle into a real-time or near-real-time exchange within the EHR.
Does This Apply to GI Practices Billing Biologics?
Yes. Any gastroenterology practice that administers physician-administered biologic infusions for inflammatory bowel disease, chronic liver conditions, or other GI diagnoses and bills those drugs under the medical benefit is directly affected by this proposed rule. The biologics most commonly billed by GI practices include infliximab (Remicade and biosimilars, J1745), vedolizumab (Entyvio, J3380), ustekinumab (Stelara, J3357 and J3358), and adalimumab administered in-office (J0135). Each of these currently requires prior authorization from most Medicare Advantage and commercial payers, and the process is almost entirely manual.
The proposed rule applies to the payers, not directly to the practices. But the operational consequence falls on the practice because electronic prior authorization only works if the provider’s EHR and practice management system can connect to the payer’s API. GI practices that do not have an EHR capable of supporting FHIR-based prior authorization exchanges will not benefit from the rule even after payers comply. Across the billing companies we vet, the practices most at risk of being left behind are the ones still running older versions of gGastro, eClinicalWorks, or standalone PM systems that have not adopted the FHIR framework. Confirming your EHR vendor’s API roadmap now, while the rule is still in the proposed stage, gives you leverage to push for an update before October 2027.
How GI Biologic Prior Authorization Changes
The table below compares the current prior authorization workflow for a biologic infusion against what the proposed rule would require once electronic interfaces go live.
| Workflow Element | Current (2026) | Proposed (October 2027) |
| Submission method | Fax, phone, or payer portal | Electronic API within EHR |
| Standard decision timeline | No federal standard (often 5-15 business days) | 7 calendar days |
| Expedited decision timeline | Varies by payer | 72 hours |
| Denial reason transparency | Often generic or missing | Specific clinical reason required |
| Drug coverage included | No (2024 rule excluded drugs) | Yes (medical-benefit drugs added) |
The most significant change for GI practices is the denial reason requirement. Under the proposed rule, payers would be required to state the specific clinical reason for any denial, not just a generic “not medically necessary” response. For biologic infusions, where step therapy and formulary restrictions drive most denials, having the specific reason in a structured electronic format means the appeal can start immediately with targeted documentation rather than a blind resubmission.
Prior authorization for biologic infusions is the most labor-intensive billing task in a GI practice, and the 2027 electronic mandate will require both EHR readiness and workflow changes. If your practice cannot confirm that your EHR supports FHIR-based prior authorization APIs, or if your team is still managing PA manually, a billing partner who specializes in gastroenterology medical billing can bridge the gap. Get matched with vetted GI billing companies, free.
What Should GI Practices Do Before October 2027?
The proposed compliance date is still more than a year away, but the preparation window is shorter than it looks. Practices that wait for the final rule to start planning will be scrambling to implement when payers flip the switch.
Confirm your EHR supports FHIR-based prior authorization. Contact your EHR vendor and ask whether their system currently supports or has a roadmap for the CMS Prior Authorization API. If the answer is unclear, escalate it now while you have time to switch or upgrade.
Audit your current biologic PA volume. Pull the number of prior authorization requests your practice submitted over the past 12 months for infliximab, vedolizumab, ustekinumab, and any other physician-administered biologic. This is your baseline for measuring the electronic system’s impact.
Map your step therapy and formulary denial patterns. Identify which payers deny initial biologic requests most often and what clinical documentation they require for approval. When electronic PA goes live, having this data structured in advance will accelerate the electronic submission.
Train staff on electronic PA workflows. The shift from fax-based to API-based submission changes the role of the PA coordinator. Clinical documentation requirements do not change, but the submission, tracking, and follow-up steps do.
Review your billing partner’s readiness. If you outsource billing or revenue cycle management, confirm that your billing company is tracking the proposed rule and has a plan for integrating electronic PA into their workflow once finalized.
Mistakes GI Practices Will Make
One question we hear constantly from practice managers is whether the electronic PA requirement means prior authorization itself is going away. It does not. The rule changes how PA requests are submitted and how fast payers must respond. It does not eliminate the requirement, reduce the clinical documentation burden, or remove step therapy protocols. Practices that assume electronic means automatic will be caught off guard when the same denials arrive faster.
Assuming this only matters for Medicare. The rule applies to Medicare Advantage, Medicaid managed care, CHIP, and marketplace plans. Traditional Medicare Part B generally does not require prior authorization for most physician-administered drugs, but the majority of GI biologic infusions are billed to MA and commercial plans that do.
Ignoring the pharmacy versus medical benefit distinction. The rule covers drugs under the medical benefit using FHIR APIs and drugs under the pharmacy benefit using NCPDP standards. If a biologic moves from medical to pharmacy benefit mid-contract, the PA workflow changes, and the practice needs to know which standard applies.
Waiting for payer compliance to act. Payers have until October 2027 to build their APIs, but EHR readiness is the practice’s responsibility. If your system cannot connect, faster payer response times do not help you.
In-House PA vs. a Billing Partner
Providers often come to us after months of delayed biologic starts and stacked PA denials that nobody had time to appeal. The prior authorization workload for a GI infusion center is fundamentally different from the PA volume in most other specialties because biologic infusions require reauthorization every 6 to 12 months, meaning the administrative cycle never stops. A billing partner with direct gastroenterology experience already manages biologic PA workflows across multiple payers, tracks step therapy requirements by plan, and appeals denials with the specific clinical documentation each payer requires. When electronic PA goes live, that partner’s systems will be among the first to integrate because their business model depends on it.
The honest test is this: if your practice cannot say how many biologic PA requests were denied last quarter, how long the average approval took, or which payer required the most appeals, your PA process is running on effort rather than data. That is the gap a specialized billing partner is built to close, and it is the gap the electronic PA mandate is designed to make visible. For context on the broader 2027 Medicare GI payment changes and how they interact with the PA workload, see our detailed guide.
Frequently Asked Questions
Does the electronic prior authorization rule eliminate PA for biologics?
No. The rule changes the submission method from manual (fax, phone, portal) to electronic (FHIR API within the EHR) and sets federal decision timelines. It does not eliminate the prior authorization requirement, remove step therapy, or reduce the clinical documentation needed for approval.
When does the electronic PA rule take effect?
CMS has proposed October 1, 2027 as the compliance date for impacted payers to support electronic prior authorization for drugs covered under the medical benefit. The rule is currently in the proposed stage (CMS-0062-P), and the final rule has not yet been published as of September 2026.
Which GI biologics are affected?
Any physician-administered drug billed under the medical benefit that requires prior authorization, including infliximab (J1745), vedolizumab (J3380), ustekinumab (J3357 and J3358), and adalimumab administered in-office (J0135). The rule applies to the payer side, covering MA, Medicaid managed care, CHIP, and marketplace plans.
Does traditional Medicare Part B require prior authorization for biologics?
Generally no. Traditional Medicare Part B does not require prior authorization for most physician-administered drugs. However, Medicare Advantage plans, which cover more than half of Medicare beneficiaries, routinely require PA for biologic infusions and are directly covered by this proposed rule.
What does my EHR need to support?
Your EHR must support FHIR-based Prior Authorization APIs to exchange PA requests and decisions electronically with payers. Contact your EHR vendor to confirm whether this capability is available now or on their development roadmap before October 2027.
Will commercial payers follow the CMS rule?
The proposed rule directly applies to MA, Medicaid managed care, CHIP, and marketplace plans. Commercial payers outside these categories are not required to comply but may adopt similar electronic PA standards voluntarily, especially as EHR and clearinghouse infrastructure matures.
Next Steps
Review the proposed rule? CMS-0062-P is available on the CMS Interoperability and Prior Authorization page for background on the drug-specific provisions.
Planning for 2027 payment changes? See our guide on the proposed 2027 Medicare GI payment changes to understand how conversion factor cuts interact with the PA workload for biologic infusions.
Ready to hand the PA workload off? Get matched with a GI billing company that already manages biologic prior authorization across multiple payers and will be positioned to integrate electronic PA when payers comply.
Prior authorization for biologic infusions consumes more staff hours per claim than any other task in a GI practice. The 2027 electronic PA mandate will change the workflow, but it will not change the documentation burden or the denial patterns. Get matched with a gastroenterology billing company that already handles biologic PA at scale and will be ready when the electronic requirement goes live. Gastroenterology Billing has connected more than 2,000 providers across all 50 states, with over 15 years in medical billing and rates starting as low as 2.95 percent. Matching is 100 percent free.
